A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes
From MaRDI portal
Publication:2057378
DOI10.1214/20-BA1205zbMath1493.62129OpenAlexW3013238781MaRDI QIDQ2057378
Ruitao Lin, Ying Yuan, Peter F. Thall
Publication date: 6 December 2021
Published in: Bayesian Analysis (Search for Journal in Brave)
Full work available at URL: https://projecteuclid.org/euclid.ba/1585360929
missing dataBayesian designoptimal treatment regimeadaptive randomizationbasket trialphase I-II clinical trial
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15) Sequential statistical design (62L05) Missing data (62D10)
Related Items (1)
Uses Software
Cites Work
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
- Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes
- Determining the Effective Sample Size of a Parametric Prior
- Missing Data in Longitudinal Studies
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- Analysis of multivariate probit models
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- An adaptive trial design to optimize dose‐schedule regimes with delayed outcomes
- Bayesian Analysis of Binary and Polychotomous Response Data
- Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity
- Prior distributions for variance parameters in hierarchical models (Comment on article by Browne and Draper)
This page was built for publication: A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes
